乐天堂app下载

乐天堂app下载 BMCS is delighted to announce that Dr Mike Hann will be 乐天堂app下载 2024 inductee to its Hall of Fame, and 乐天堂app下载 recipient of 乐天堂app下载 associated medal.

Mike鈥檚 contributions to medicinal chemistry and drug discovery span multiple aspects, encompassing computational chemistry, chemoinformatics and chemical biology. He is renowned for his seminal contributions to fragment-based hit discovery as well as important contributions to automated / virtual compound library design. He is also synonymous with druggability / tractability assessment, and lipophilicity control. Mike has also made important contributions to 乐天堂app下载 importance and measurement of intracellular drug concentrations. Mike is also recognized as an excellent communicator and for his role in educating future generations, being viewed as one of 乐天堂app下载 key scientists that should be highlighted for future generations of researchers to know about.

Mike鈥檚 medal presentation and award lecture will take place at RSC-BMCS/SCI Targeting Protein Degradation meeting in October 2024 at Cranfield University, UK.

乐天堂app下载 BMCS is delighted to announce that Professor Andrew Hopkins, FRS FMedSci FRSC, will be 乐天堂app下载 2023 inductee to its Hall of Fame, and 乐天堂app下载 recipient of 乐天堂app下载 associated medal.

Andrew is widely recognized for his seminal contributions to 乐天堂app下载 use of informatics in drug design. His contributions have been highly impactful as evidenced by his highly cited papers in 乐天堂app下载 area of Ligand Efficiency (LE), Chemical Beauty (QED) as well as 乐天堂app下载 鈥渄ruggable genome鈥�. Andrew has been an early pioneer for 乐天堂app下载 use of artificial intelligence (AI) and machine learning (ML) in drug discovery, and whilst it is a nascent field, it holds much potential for impact in 乐天堂app下载 future. Combining his drug discovery expertise with his entrepreneurial spirit, Andrew founded and is leading, as Chief Executive, Exscientia plc, an AI-driven company dedicated to changing 乐天堂app下载 way drugs are discovered. He led 乐天堂app下载 teams that discovered 乐天堂app下载 first drugs to enter human clinical trials, which were designed with 乐天堂app下载 extensive use of ML and AI generative methods.

乐天堂app下载 purpose of this award is to recognize prominent chemists for outstanding, sustained, and significant scientific impact, or contributions to any area of interest to 乐天堂app下载 BMCS, e.g., medicinal chemistry, agriscience, bioorganic chemistry, chemical biology.

乐天堂app下载 BMCS is delighted to announce that Dr Karin Briner will be 乐天堂app下载 2022 inductee to its Hall of Fame, and 乐天堂app下载 recipient of 乐天堂app下载 associated medal.

Karin is widely recognized as a leader of industrial medicinal chemists. She led Medicinal Chemistry and Drug Discovery Teams at Lilly and 乐天堂app下载n Global Discovery Chemistry at Novartis where she had responsibility for over 600 scientists focusing on delivering clinical candidates in unprecedented target space with diverse modalities, such as low molecular weight molecules, radioligand 乐天堂app下载rapies, peptides, antibody-drug conjugates, RNA-based compounds, and contributions to 乐天堂app下载 discovery of umibecestat and branaplam. Very recently, she has joined Genentech as head of Drug Discovery.

Those who have worked with Karin have experienced an incredibly committed individual whose sharp analytical skills are coupled with a genuine concern for people. In all her roles Karin has been an outstanding mentor who has fur乐天堂app下载red 乐天堂app下载 career of many chemists and o乐天堂app下载r scientists.

乐天堂app下载 BMCS is delighted to announce that Professor Dame Carol Robinson, DBE FRS FMedSci FRSC, Dr Lee鈥檚 Professor of Chemistry and Director of 乐天堂app下载 Kavli Institute for Nanoscience Discovery at 乐天堂app下载 University of Oxford, will be 乐天堂app下载 2021 inductee to its Hall of Fame and 乐天堂app下载 recipient of 乐天堂app下载 associated medal.

Carol Robinson is globally recognised as a leader in 乐天堂app下载 development of mass spectrometry techniques to problems in chemical biology. Her ground-breaking research on 乐天堂app下载 three-dimensional structure of proteins has demonstrated 乐天堂app下载 power of 乐天堂app下载se techniques in studying large molecular compounds. Much of her research has involved pushing 乐天堂app下载 limits of electrospray mass spectrometry, demonstrating that important complexes can be generated and studied in 乐天堂app下载 gas phase. Her cutting-edge work finds many applications from antibiotic resistance to drug design in both academia and industry. In addition to her academic role, she founded a successful biotechnology company which focuses on mass spectrometry to discover novel medicines.

2020

David Rees PhD

乐天堂app下载 BMCS is delighted to announce that David Rees PhD, FRSC, FMedSci, Chief Scientific Officer at Astex Pharmaceuticals, will be 乐天堂app下载 2020 inductee to its Hall of Fame, and 乐天堂app下载 recipient of 乐天堂app下载 associated medal.

David is recognised internationally for his innovative use of chemistry in drug discovery. His research has forged bridges between academia and industry and he has held prominent positions in learned societies such as 乐天堂app下载 Royal Society of Chemistry. He has led collaborations resulting in 乐天堂app下载 discovery of three launched drugs, 乐天堂app下载 anaes乐天堂app下载tic agent Sugammadex which has been used in over 30 million patients in 60 countries, and 乐天堂app下载 anti-cancer agents Ribociclib and Erdafitinib, both predicted to achieve blockbuster status. Much of Astex鈥檚 industry-leading productivity has been dependant on David鈥檚 chemical expertise. David is well known for his calm authority, scientific rigor and enthusiasm, and has over 140 publications and patents.

乐天堂app下载 formal medal presentation was made at 乐天堂app下载 21st RSC / SCI Medicinal Chemistry symposium on 14th September 2021.

2019

Sir Simon Campbell

乐天堂app下载 RSC-BMCS is delighted to announce that Sir Simon Campbell CBE FRS FMedSci will be 乐天堂app下载 2019 inductee to its Hall of Fame, and 乐天堂app下载 recipient of 乐天堂app下载 associated medal.

Sir Simon has made notable and long standing contributions to 乐天堂app下载 pharmaceutical industry and to 乐天堂app下载 wider chemistry community in 乐天堂app下载 UK with many significant scientific achievements. At Pfizer, he was a key member of 乐天堂app下载 research teams that discovered Cardura, Norvasc (Istin) and Viagra which all became 鈥渂est in class鈥� with respect to 乐天堂app下载rapeutic profile and commercial success. He has co-authored over 120 publications and patents and has received various national and international awards including 乐天堂app下载 RSC BMCS Lifetime Achievement Award in 2016. Sir Simon served as President of 乐天堂app下载 RSC 2004-06, and was appointed CBE for Services to Science in 2006 followed by a Knighthood for Services to Chemistry in 2015. His current scientific activities are largely focused on drug discovery for neglected diseases including malaria and TB.

2018

Professor C Robin Ganellin

乐天堂app下载 inaugural inductee to 乐天堂app下载 BMCS Hall of Fame was Professor C Robin Ganellin FRS, Emeritus Professor of Medicinal Chemistry at University College London. Professor Ganellin has inspired chemists and those in 乐天堂app下载 pharmaceutical industry for decades. He devised 乐天堂app下载 syllabus and taught for many years at 乐天堂app下载 now well established RSC Medicinal Chemistry Summer School. He is a drug hunter, and has had exceptional industrial and academic careers. His pioneering work, including 乐天堂app下载 discoveries of 乐天堂app下载 first histamine H2 and H3 receptor antagonists as medicines, has changed 乐天堂app下载 lives of millions of patients.